Cosunter(SZ:300436) Xin Lang Cai Jing·2025-11-11 06:27Group 1 - The core viewpoint of the news is that Guangshentang's stock price increased by 5.82%, reaching 108.92 CNY per share, with a trading volume of 916 million CNY and a turnover rate of 6.61%, resulting in a total market capitalization of 17.347 billion CNY [1] - Guangshentang Pharmaceutical Co., Ltd. is located in Fuzhou, Fujian Province, and was established on June 28, 2001, with its listing date on April 22, 2015. The company specializes in the research, production, and sales of nucleoside antiviral drugs for hepatitis B [1] - The main business revenue composition of Guangshentang is 98.54% from liver and gallbladder disease drugs and 1.46% from other supplementary products [1] Group 2 - From the perspective of the top ten circulating shareholders, a fund under China Europe Fund ranks among Guangshentang's top shareholders. The China Europe Medical Health Mixed A Fund (003095) reduced its holdings by 1.1365 million shares in the third quarter, now holding 708,100 shares, which accounts for 0.52% of the circulating shares [2] - The estimated floating profit for the China Europe Medical Health Mixed A Fund today is approximately 4.2418 million CNY [2] - The China Europe Medical Health Mixed A Fund was established on September 29, 2016, with a latest scale of 16.977 billion CNY. Year-to-date returns are 21.33%, ranking 4326 out of 8147 in its category, while the one-year return is 10.73%, ranking 5278 out of 8056 [2]